CRI Pilot Innovative Research Award: A Mobile App for Adverse Event Reporting in the Treatment of Infantile Hemangiomas
Dr. Beth Drolet (principal investigator) and Dr. Kristen Holland (co-principal investigator) received a one-year award in the amount of $33,252 from the Children’s Research Institute. The major goal of this project is to use cutting-edge mobile technologies to address the lack of toxicity data in the off-label use of beta blockers in the treatment of infantile hemangiomas, by developing a parent-reported outcomes (PRO) tool for the collection of adverse event data during infantile hemangioma treatment.
This PRO Tool will consist of a secure, hosted technology platform with an associated user-centered mobile app that is engineered to engage families with infantile hemangiomas. Using a typical mobile device, parents will report adverse events in real-time, enabling rapid collection of large amounts of data related to the treatment of hemangiomas using beta blockers.
Successful completion of this project can potentially shift the paradigm of clinical trial design and support the use of this tool in future pediatric clinical trials.
Pediatric Trials Network Subcontract: Pediatric Thought Leader for Timolol in the “Pharmacokinetics of Understudied Drugs Administered to Children per Standard... more
Dr. Siegel (principal investigator) and the Medical College of Wisconsin received a three-year, $1.38 million grant from the National Institute... more